The young small-cap healthcare company we review in this report is growing rapidly and has a large total addressable market opportunity. It also has an attractive recurring revenue model with a very high retention rate (customers like it) and attractively improving margins (as the business continues to scale). The company provides personalized data-driven solutions that help individuals understand healthcare better, as well as assisting them in navigating workplace benefits available to them. In this report, we review the business, the opportunity, financials, valuation and risks. We conclude with our opinion on investing.
Portfolio Update: 3 New Buys, 1 Complete Sell, + Some Rebalancing
I don’t trade often because I am a disciplined long-term investor. However, I have just completed 3 new buys, and 1 complete sell (plus a variety of normal rebalancing trades) within the Blue Harbinger Disciplined Growth portfolio. I have also updated the “Buy Under” prices (and thereby ratings) of a variety of existing positions within the Blue Harbinger Income Equity portfolio and the Disciplined Growth portfolio. This report reviews all of the latest updates, as well as why I believe these two portfolios are positioned for continuing long-term success, in a big way!
Fooled by Narratives: Three (3) Stocks Worth Considering for Purchase, Now
The investment news media is more interested in generating advertising dollars than it is in actually helping anyone with investments. Their goal is to tell the most ridiculous sensationalized investment stories they can get away with in order to garner more readers, listeners, clicks and ultimately advertising dollars. One of the most common ploys they use to implement their unscrupulous agenda is the false narrative. They’re basically dishonest, uncaring and greedy. In this report, we share 3 highly attractive investment ideas that are hiding in plain sight thanks to the media’s totally disingenuous false narratives.
A Note on Recent Market Volatility
The market has been volatile this year, and it’s left a lot of investors feeling very uncomfortable. Contributing factors have ranged from a surge in oil prices, to upward moves in interest rates, the unwinding of many “pandemic trades,” bitcoin narratives, market fear mongers, and of course the ever present chorus of nonsensical get-rich-quick people. We have some very strong advice for anyone feeling unsettled about the market. If you’ve been following Blue Harbinger long enough then you’ve likely heard it many times before. It’s worth repeating now…
Life Sciences Cloud Software Company: Even More Attractive on the Recent Price Pullback
There is a large and growing demand for cloud-based software in the life sciences industry, and the company we review in this report is the clear market leader (with a lot of long-term upside). And despite a recent earnings beat and guidance raise (on top of its already rapidly growing business) the shares have recently sold off (as part of the broader market’s recent sell off of top growth stocks in general). We believe these factors have combined to create an attractive buying opportunity, and we share all the details in this report, including a review of the business, growth prospects, valuation and risks. If you are a long-term investor, these shares are worth considering for a spot in your portfolio.
Attractive Growth, Share Price Pullback
If you are looking for a steady dividend-growth stock, this report is not for you. However, if you are looking to add a little powerful long-term price appreciation to your portfolio, these shares are worth considering, especially on the recent price pullback. The company is well-positioned as a premium brand in China, it enjoys rapid sales growth and a large and growing total addressable market, and it has the backing of the Chinese government. In this report, we review the company’s business model, market opportunity, COVID-19 impacts, competitive position, valuation and risks. We conclude with our opinion on whether the company offers an attractive risk-reward versus its long-term growth opportunity.
Performance Update: More Gains & The Pandemic Trade’s Future
The Blue Harbinger “Disciplined Growth” portfolio and the “Income Equity” portfolio both posted positive gains (again) in February (thereby extending their growing long-term track records of top performance). However, if you haven’t noticed, the market has been particularly volatile for top growth stocks over the last few weeks. More specifically, the “pandemic trade” is crashing. In this report, we share the latest performance of our top idea portfolios, and offer some tried and true advice (and specific ideas) about current market conditions going forward.
Top 5 High-Growth Stocks, that Just Sold Off
This report is a continuation of our free report “Top 10 Growth Stocks that just sold off,” but in this members-only edition—we include the top 5. As mentioned, it was a terrible week for top growth stocks, but there are plenty of very attractive opportunities (babies that have been thrown out with the bathwater). In this report, we countdown our full top 10 high growth stocks that just sold off, starting with #10 and finishing with our #1 top idea.
This Internet Infrastructure Company: Worth Considering on the Pullback
The market has been volatile this week, especially top growth stocks. This report covers an attractive internet infrastructure and security company (i.e. a top growth stock) that has been increasing revenues very rapidly and has a very large total addressable market (for continued high growth in the long-term). And while the shares of top growth stocks are never going to be cheap, this week’s price pullback has created a small margin of safety thereby creating an increasingly tempting entry point for long-term investors. In this report, we consider the business model, competitive strength, financial position, and finally conclude with our opinion on investing.
The Top 5 High-Growth Stocks: Market Melt-Up Edition
Since the depths of the initial coronavirus selloff in 2020, the market has climbed dramatically higher, and the ascent has been even more dramatic for top growth stocks. In light of these dramatic price gains, many investors are getting nervous and wondering if they should dump their high growth stocks altogether in order to avoid a potential market selloff that media fear mongers warn us of daily. Of course, what you do with your own investment dollars is up to you entirely. We’d never advocate for blindly buying all growth stocks in general, but we do believe their continues to be an ample supply of individual high growth businesses that are worth investing in regardless of what happens to the overall market indexes. And in this report, we countdown our top 10 high growth stocks, starting with #10 and finishing with our #1 top idea.
Palantir Options Trade: Very High Upfront Income
With the price pullback over the last month, and an earnings announcement coming up in less than two weeks, data analytics company Palantir, is setting up for a very interesting and very high upfront income generating options trade. We successfully implemented a similar Palantir trade at the end of November, but those contracts expired (quite profitably) on January 15, and conditions are again attractive for a similar trade. In this report, we review the trade details. We believe it’s an attractive trade to place today and potential over the next few trading days, as long as the price doesn’t move too dramatically before then.
Powerful Growth Trajectory: This New Value-Based Health-Care Model Company
This recently public company (August 2020) is on a tremendous growth trajectory as it delivers a highly differentiated, technology-enabled, value-based care model for Medicare. The continuing growth opportunities stem from the rapid shift of patients to value-based care and increasing patient consumerism. This report reviews the business, its growth prospects, valuation and risks, and then concludes with our opinion about investing.
NovoCure: Large Opportunities Ahead
NovoCure (NVCR) is a global oncology company with patented “Tumor Treating Fields” (“TTF”) technology. It has multiple programs in phase 2 and phase 3 of clinical trials which can potentially result in exponential revenue growth and Total Addressable Market (“TAM”) expansion. As a result, and due to improving market penetration, the stock more than doubled in 2020. In this report, we review NovoCure’s business model, competitive strengths, financial position and valuation, and then conclude with our opinion on investing from a risk-versus-reward standpoint.
Fiverr: Attractive High-Income Options Trade
Fiverr (FVRR) is a global marketplace connecting freelancers and businesses for their digital service needs. The business was already growing rapidly, and the pandemic accelerated it. The trade in this report generates very high upfront premium income (that you get to keep no matter what) and it gives you a chance to pick up shares of this attractive business at a significantly lower price. The premium income available on this trade is very high because the share price has been volatile, but the business remains attractive in the long-term. We believe this is an attractive trade to place today and potentially over the next few trading sessions as long as the share price doesn’t move too dramatically before then.
Magnite: Massive Total Addressable Market
Magnite is a digital advertising industry company that has made inroads into the fast-growing Connected TV (“CTV”) space (thanks to its April 2020 merger with Telaria). The company is now the world’s largest sell-side platform (“SSP”) for buying and selling advertising inventory available across multiple channels, including mobile, desktop and CTV. Magnite experienced demand erosion in 2020 as the global pandemic resulted in reduced ad spending. However, revenues have started to re-accelerate, and the share price has been rebounding dramatically off 2020 lows. What’s more, there is a massive total addressable market opportunity ahead. In this report, we analyze Magnite’s business model, its market opportunity, challenges, current valuation, and conclude with our opinion on investing (including a specific trading idea).
New Options Trade: Very High Upfront Income, Bullish Vertical Put Spread
The market has been strong, particularly technology stocks, and in this report we review a very attractive CPaaS (Communication Platform as a Service) technology stock. In particular, we share an attractive options trade, that generates high upfront premium income (that you get to put in your pocket and keep no matter what), and the trade also gives you a shot of picking up shares of this very attractive CPaaS stock (if the price falls below your strike price prior to the option contract expiration in 1-month). We believe this is a very attractive trade to place today, and potentially over the next few trading sessions, as long as the price doesn’t move too dramatically before then.
FuboTV: The Ride Will be Bumpy
FuboTV is a “sports first” streaming platform with a very high growth trajectory and a large total addressable market (i.e. lots of room to run). Specifically, it is benefiting from the the secular decline in traditional TV, the shift to connected TV advertising, and the potential growth in online sports wagering. This report reviews the health of the business, growth prospects, valuation, risks and concludes with our opinion on investing.
New Options Trade: Very High Upfront Income, Attractive DevOps Company
There is a certain breed of companies that has continued to perform extremely well in our rapidly evolving economy (i.e. software-as-a-service businesses that operate on a subscription basis, with high revenue growth and large total addressable markets). We write about one such company (that focuses on “dev ops”) in this report that completed its initial public offering in September, and the share price has been steadily reverting lower after an initial share price pop to more than double the IPO price. In particular we write about an attractive high income-generating options trade that also gives us a chance to pick up shares of this compelling company at an even lower price. We believe this is an attractive trade to place today—and potentially into early next week—as long as the share price doesn’t move too dramatically before then.
This Chip Stock: A Rare and Powerful Tech Turnaround
It’s not often that a tech company can successfully reinvent itself considering immense global competition in a rapidly changing marketplace. However, this report covers a semiconductor (chip) company, that has successfully turned itself around and has continuing powerful long-term price appreciation potential ahead. In this report, we take a detailed look at the business, the market opportunity, risks and valuation, and then conclude with our opinion on investing.